COVID-19: A Brief Overview of the Discovery Clinical Trial
Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
Pharmaceuticals 2020, 13(4), 65; https://doi.org/10.3390/ph13040065
Received: 4 April 2020 / Revised: 8 April 2020 / Accepted: 9 April 2020 / Published: 10 April 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.
View Full-Text
Keywords:
chloroquine; COVID-19; hydroxychloroquine; lopinavir/ritonavir; remdesivir; repurposing; SARS-CoV-2
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Vanden Eynde, J.J. COVID-19: A Brief Overview of the Discovery Clinical Trial. Pharmaceuticals 2020, 13, 65. https://doi.org/10.3390/ph13040065
AMA Style
Vanden Eynde JJ. COVID-19: A Brief Overview of the Discovery Clinical Trial. Pharmaceuticals. 2020; 13(4):65. https://doi.org/10.3390/ph13040065
Chicago/Turabian StyleVanden Eynde, Jean J. 2020. "COVID-19: A Brief Overview of the Discovery Clinical Trial" Pharmaceuticals 13, no. 4: 65. https://doi.org/10.3390/ph13040065
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
